Imbruvica (Ibrutinib)

Imbruvica targets B‑cell receptor signaling and is used in a range of B‑cell malignancies and related conditions.

• Chronic lymphocytic leukemia (CLL): improves progression‑free survival and disease control.
• Mantle cell lymphoma (MCL): induces tumor regression and prolongs remission.
• Waldenström macroglobulinemia: reduces IgM levels and disease burden.
• Marginal zone lymphoma: achieves disease control and symptom relief.
• Small lymphocytic lymphoma: prolongs remission duration.
• Chronic graft‑versus‑host disease (cGVHD): alleviates disease manifestations and improves quality of life.

• Ibrutinib binds irreversibly to the cysteine residue in the active site of Bruton's tyrosine kinase, a key enzyme in the B‑cell receptor signaling cascade. By blocking BTK activity, the drug prevents downstream activation of NF‑κB, MAPK and AKT pathways, leading to inhibition of malignant B‑cell proliferation, survival and migration. The inhibition is sustained for the lifespan of the target cell, providing continuous pathway suppression.

Ibrutinib is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Diarrhea: watery stools, usually mild to moderate.
• Nausea: occasional upset stomach.
• Fatigue: persistent tiredness.
• Bruising or bleeding: easy bruising or nosebleeds.

Serious or Rare Side Effects

• Atrial fibrillation: irregular heart rhythm that may require medical attention.
• Severe infections: opportunistic or bacterial infections requiring treatment.
• Tumor lysis syndrome: rapid tumor breakdown leading to metabolic disturbances.

When prescribing Imbruvica, clinicians should observe several precautionary measures to minimize risk.

• Monitor blood counts: perform regular CBC to detect cytopenias.
• Assess infection risk: watch for signs of bacterial, fungal or viral infections.
• Evaluate cardiac function: baseline ECG and periodic monitoring for arrhythmias.
• Avoid strong CYP3A4 inhibitors: dose adjustment or alternative therapy may be needed.
• Adjust in hepatic impairment: consider reduced dose in moderate liver dysfunction.
• Store at ambient temperature: keep tablets in original container, protect from moisture and heat.

Ibrutinib may interact with other medicines that affect its metabolism or hemostasis.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can markedly increase ibrutinib exposure.
• Anticoagulants (e.g., warfarin, direct oral anticoagulants): may enhance bleeding risk.
• Antiplatelet agents (e.g., aspirin, clopidogrel): increase risk of hemorrhage.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, phenytoin): may reduce drug levels and efficacy.
• Proton pump inhibitors: may modestly affect absorption; monitor therapeutic response.
• Live attenuated vaccines: consider timing as immunosuppression may affect vaccine efficacy.